Rubella (German Measles) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Rubella (German Measles) – Pipeline Review, H2 2016’, provides an overview of the Rubella (German Measles) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Rubella (German Measles), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Rubella (German Measles) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Rubella (German Measles)

The report reviews pipeline therapeutics for Rubella (German Measles) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Rubella (German Measles) therapeutics and enlists all their major and minor projects

The report assesses Rubella (German Measles) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Rubella (German Measles)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Rubella (German Measles)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Rubella (German Measles) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Biological E. Limited

Daiichi Sankyo Company, Limited

GlaxoSmithKline Plc

Indian Immunologicals Limited

Prometheon Pharma, LLC

Sinovac Biotech Ltd.

Zydus Cadila Healthcare Limited

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rubella (German Measles) Overview 6

Therapeutics Development 7

Pipeline Products for Rubella (German Measles) - Overview 7

Pipeline Products for Rubella (German Measles) - Comparative Analysis 8

Rubella (German Measles) - Therapeutics under Development by Companies 9

Rubella (German Measles) - Therapeutics under Investigation by Universities/Institutes 10

Rubella (German Measles) - Pipeline Products Glance 11

Late Stage Products 11

Clinical Stage Products 12

Early Stage Products 13

Unknown Stage Products 14

Rubella (German Measles) - Products under Development by Companies 15

Rubella (German Measles) - Products under Investigation by Universities/Institutes 16

Rubella (German Measles) - Companies Involved in Therapeutics Development 17

Beijing Minhai Biotechnology Co., Ltd 17

Beijing Tiantan Biological Products Co., Ltd. 18

Biological E. Limited 19

Daiichi Sankyo Company, Limited 20

GlaxoSmithKline Plc 21

Indian Immunologicals Limited 22

Prometheon Pharma, LLC 23

Sinovac Biotech Ltd. 24

Zydus Cadila Healthcare Limited 25

Rubella (German Measles) - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Combination Products 27

Assessment by Route of Administration 28

Assessment by Molecule Type 30

Drug Profiles 32

(measles + mumps + rubella + varicella) vaccine - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

(measles + mumps + rubella + varicella) vaccine - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

(measles + mumps + rubella) vaccine - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

(measles + mumps + rubella) vaccine - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

(measles + mumps + rubella) vaccine - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

(measles + rubella + varicella) vaccine - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

(measles + rubella) vaccine - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

(measles + rubella) vaccine - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

(measles [strain Schwarz] + mumps [strain RIT 4385] + rubella [strain Wistar RA 27/3]) vaccine - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

rubella vaccine - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

VN-0102 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Rubella (German Measles) - Dormant Projects 43

Appendix 44

Methodology 44

Coverage 44

Secondary Research 44

Primary Research 44

Expert Panel Validation 44

Contact Us 44

Disclaimer 45

List of Tables

List of Tables

Number of Products under Development for Rubella (German Measles), H2 2016 7

Number of Products under Development for Rubella (German Measles) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Comparative Analysis by Unknown Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

l 16

Rubella (German Measles) – Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2016 17

Rubella (German Measles) – Pipeline by Beijing Tiantan Biological Products Co., Ltd., H2 2016 18

Rubella (German Measles) – Pipeline by Biological E. Limited, H2 2016 19

Rubella (German Measles) – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 20

Rubella (German Measles) – Pipeline by GlaxoSmithKline Plc, H2 2016 21

Rubella (German Measles) – Pipeline by Indian Immunologicals Limited, H2 2016 22

Rubella (German Measles) – Pipeline by Prometheon Pharma, LLC, H2 2016 23

Rubella (German Measles) – Pipeline by Sinovac Biotech Ltd., H2 2016 24

Rubella (German Measles) – Pipeline by Zydus Cadila Healthcare Limited, H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Stage and Route of Administration, H2 2016 29

Number of Products by Stage and Molecule Type, H2 2016 31

Rubella (German Measles) – Dormant Projects, H2 2016 43

List of Figures

List of Figures

Number of Products under Development for Rubella (German Measles), H2 2016 7

Number of Products under Development for Rubella (German Measles) – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Assessment by Combination Products, H2 2016 27

Number of Products by Routes of Administration, H2 2016 28

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 28

Number of Products by Molecule Types, H2 2016 30

Number of Products by Stage and Molecule Types, H2 2016 30

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports